For most of the last decade this was a thought experiment. In 2026 it is a live commercial question and the answer investors need is not “yes eventually” but something more useful: what is technically achievable now, what is structurally blocked and where the value actually accrues. The short version: an AI native EHR is buildable and parts of it are already shipping. But the constraint has stopped being model capability. It is now data plumbing, regulatory conformity, liabil

The acquisition represents a decisive structural consolidation within the global digital imaging components sector. Varex, headquartered in Salt Lake City, Utah, employs approximately 2,400 people across operations in North America, Europe, and Asia. The company maintains a decades-long heritage in designing and manufacturing high-specification X-ray sources, flat-panel digital detectors, photon-counting detectors, high-voltage interconnects and imaging software.

SleepFM is a multimodal artificial intelligence foundation model engineered to derive latent representations of human physiology directly from polysomnographic recordings. Trained on a curated dataset exceeding 585,000 hours of PSG recordings from approximately 65,000 individuals, SleepFM establishes a novel paradigm in computational medicine. By shifting away from narrow, single-task deep learning models toward scalable, self-supervised pretraining, the model extracts high-d

For founders, investors and acquirers operating in European HealthTech, understanding this new shape of the market matters more than tracking any single quarterly funding figure. The headline numbers now tell contradictory stories depending on which slice you examine, European digital health funding in the first quarter of 2026 fell 44% year on year, yet first-half funding rose 60% over the same period. Both figures are accurate. Reconciling them is the key to understanding w

Financial markets have witnessed a structural decoupling between large cap healthcare equities and technology stocks, particularly those tied to the artificial intelligence (AI) capital expenditure cycle. Historically, the relationship between the Health Care Select Sector SPDR Fund (XLV) and semiconductor benchmarks such as the VanEck Semiconductor ETF (SMH) was characterized by loose positive or neutral correlations. Over multi-year economic expansion phases, both sectors f

Nelson Advisors UK HealthTech Pulse > August 10th to 14th 2026. 1. EPR pipeline keeps filling, but capital is the choke point. 2. Ambient voice is scaling and now has a safety spotlight on it. 3. Procurement and programme money keeps moving at the smaller end. 4. NHS-built IP is going commercial. 5. Funding and M&A: clinical-grade AI attracts capital; documentation consolidates. 6.⁠ ⁠Ambient voice technology is scaling and drawing scrutiny at the same time. 7.⁠ ⁠Trusts

Major developments across the European HealthTech, MedTech, and Health AI sectors highlight regulatory realignments, venture shifts toward deep-tech diagnostics, and clinical integration. Recent developments across European Health AI highlight regulatory enforcement milestones under the EU AI Act, institutional alignment between the EMA and EISMEA, and an investor shift toward "clinical plumbing" and diagnostic deep-tech. Recent developments across the European MedTech land

The rapid transformation of the NHS App from a basic vaccine passport repository into England’s primary digital healthcare gateway represents one of the most significant structural reconfigurations in the history of the National Health Service. As NHS England centralises patient identity, clinical triage, appointment scheduling, prescription tracking and messaging under a single state-managed application, the UK healthtech market faces a pivotal strategic dilemma.

For lower to middle market founders leading enterprises generating between $5 million and $50 million in annual revenue or $1 million to $25 million in EBITDA, the acquisition journey rarely originates from a formal board resolution to initiate a sale process. While an unexpected approach serves as clear validation of a company's market traction, the initial 30 days following first contact represent a critical strategic pivot point. A founder’s immediate posture determines wh

Musculoskeletal conditions represent one of the most substantial financial and operational burdens placed upon global healthcare systems and national economies. In the United Kingdom alone, over 20 million people suffer from an MSK condition, generating between 18% and 30% of all general practitioner (GP) consultations and costing the National Health Service (NHS) approximately £5 billion annually.

The general availability of Oracle Health’s artificial intelligence-backed patient portal across the United States marks a key development in consumer health informatics. Originally previewed at the Oracle Health and Life Sciences Summit, the portal leverages foundation models developed by OpenAI directly within the core Oracle Health Electronic Health Record (EHR) ecosystem. This deployment seeks to resolve a persistent friction point in digital patient engagement: the acces

On August 12th, 2026, Radar Healthcare, a provider of risk, quality and compliance software for the health and social care sectors, formally announced its acquisition of patient experience and patient-reported outcomes platform Cemplicity. Backed by private equity firm Marlin Equity Partners, a global investment firm with over $9 billion in capital commitments, Radar Healthcare has executed this transaction as part of an aggressive platform-expansion strategy.

The European healthcare sector is undergoing a structural paradigm shift in digital front door architecture. Driven by severe clinical workforce shortages, expanding emergency department backlogs and rising chronic disease prevalence, healthcare systems are transitioning from passive digital directories to clinically validated artificial intelligence (AI) solutions for symptom assessment, triage, and patient navigation. These systems utilise sophisticated clinical reasoning e

Operating in the lower to middle market, specifically targeting companies with Enterprise Values (EV) ranging from $25 Million to $250 Million, Nelson Advisors LLP represents a prime example of this specialised advisory model. Headquartered in London, the firm leverages more than 15 years of operational healthcare technology experience derived from founding, funding, scaling and exiting HealthTech ventures since 2011, combining institutional investment banking execution with

Hims & Hers Health, Inc. has undergone a fundamental structural evolution, transitioning from a direct-to-consumer marketplace for stigmatised wellness products into a technology-driven, global healthcare platform. Originally launched to provide streamlined access to generic therapies in hair care and sexual health, the company has expanded its clinical breadth to encompass dermatology, mental health, weight management, cardiovascular care, hormone optimisation and direct-to-